Professionals 225 Users Online

Autologous Conditioned Plasma Market

Growing incidences of knee osteoarthritis to create lucrative market demands for autologous conditioned plasma.

Autologous Conditioned Plasma Market by Composition (Pure Platelet-Rich Plasma (P-PRP), Pure Platelet-Rich Fibrin (P-PRF), Leukocyte- and Platelet-Rich Plasma (LPRP) and Platelet-Rich Fibrin)

Autologous Conditioned Plasma Market Outlook (2023 to 2033)

The Global revenue from the Autologous Conditioned Plasma Market was around US$ 475.6 Million in 2022, with the global market expected to grow at a CAGR of 11.1% to reach a valuation of around US$ 1.52 Billion by the end of 2033.

Market Size (2023)

US$ 531.7 Million

Projected Market Value (2033)

US$ 1,519.7 Million

Global Market Growth Rate (2023 to 2033)

11.1% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, autologous platelet-rich plasma held a market share of around 86.5% in the global market, in 2022. Overall, autologous conditioned plasma market account for nearly 1.0% of revenue share in the global non-invasive aesthetic treatment market, which was valued at around US$ 61.2 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Market from 2015 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 12.0% in the last 7 years from 2015 to 2022.

In comparison to invasive surgeries, platelet-rich plasma (PRP) therapy is a minimally invasive method that is efficient, highly effective, and economical. It also accelerates tissue regeneration, shortens recovery times, and has greater success rates, due to such factors it is expected that the global market will rise.

According to the WHO (World Health Organization), musculoskeletal injuries are the most common cause of chronic pain and physical disability and affect millions of individuals worldwide.

  • Worldwide, 1.71 billion people suffer from musculoskeletal conditions. Back pain is the sole top reason for disability in more than 160 countries, and musculoskeletal conditions are the main cause of disability globally.

However, platelet rich plasma therapy, which encourages secure and efficient wound healing, is an appealing and promising alternative to surgery for treating musculoskeletal injuries. Due to its strong regeneration capabilities and great therapeutic potential, PRP therapy is widely used in clinical settings for treating musculoskeletal injuries and disorders that are associated to them.

Soft tissue degeneration and associated problems, particularly those of the knee, are influenced by ageing. Knee osteoarthritis can be effectively treated with autologous PRP therapy, which involves giving patients own concentrated platelets. The older population is gradually getting increasing, which will speed up market growth in the future.

  • In the U.S., 23.7% of adults, or roughly 58.5 million people, have arthritis, according to the CDC. Arthritis is more common in women (23.5%) compared with men (18.1%), arthritis prevalence increases with age.

The global market is likely to show high growth over the coming years at a CAGR of 11.1% and reach a global market size of US$ 1.52 Billion by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Market Grow?

Increased FDA Regulatory Approvals and Expanding PRP Application in the Sports Medicine Industry to Create Lucrative Potential for the Market

In the field of sports medicine, injured athletes who require a quick recovery usually opt for autologous conditioned plasma, which is expected to develop the market throughout the forecast period.

  • Sports injuries most commonly involve the Achilles tendon (AT). According to studies published in the journal of Sports Medicines and Health Sciences, 2022, more than 50% of male professional runners have AT cumulatively throughout their professional career, runners have a ten times higher risk of AT than their peers who are not involved in extreme physical exercises. Incidence rates of AT were 7.7% among basketball players, according to an epidemiological investigation published in the same journal. Athletes can resume their post-injury activity levels thanks to the development of PRP injections, which hasten the healing of the lesion.

The approval to market PRP preparation devices is provided by the FDA 510(k) application. Systems that are "substantially equivalent" to a presently marketed device may be introduced to the market with the help of a 510(k) application. Today's market has a wide variety of PRP preparation systems that have received FDA approval. Increasing FDA regulatory approvals will further expand the market.

EmCyte Corporation announced on June 11, 2019, that the FDA had approved the PureBMC® Supraphysiologic Concentrating System for making a cell concentrate from platelet concentrate and bone marrow aspirate.

Another factor propelling the market's growth is the increased use of autologous conditioned plasma fibrin therapy (P-PRF). Fibrin membranes contain numerous growth factors and high platelet content, which are devoid of anticoagulants or other biochemical modifications that aren't natural. P-PRF treatment is a second-generation platelet concentrate that has been found to accelerate and promote wound healing.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Market Growth Be Affected in Any Way?

“Absence of Uniformity in Preparation and Dosage of Autologous Blood Concentrate”

One of the most challenges in analyzing the clinical outcomes of PRP therapy in orthopedic injuries is the lack of homogeneity in dosage, preparation, and platelet-separation techniques. Specific changes in the concentration of growth factors, platelet activators, leukocytes, and other cellular components reduce the generalization ability of clinical and fundamental research discoveries, making it challenging to interpret any findings, which may impede the growth of the market as a whole.

Although there are many researches now being conducted to evaluate the efficacy of PRP therapy in orthopedic applications. There is not enough scientific evidence to determine the degree of PRP therapy's efficacy. The PRP market's expansion is thought to be significantly constrained by therapy failure. It has been contended repeatedly since the discovery of PRP therapy that it does not provide any significant therapeutic effect in pain management or rate of wound healing.

  • PRP therapy failed efficacy testing for a number of therapeutic segments, including total knee arthroplasty (TKA) surgery and rotator cuff repair, according to a review paper from the NCBI.
Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the United States Market Booming?

“Presence of Well Established Players and High Demands from End Users”

The United States accounted for around 91.9% market share in the North America market in 2022.

The expansion of the United States market can mainly be attributed to the presence of numerous manufacturing facilities inclined to develop novel PRP-based treatment methods, high end-user procurement at hospitals and clinics, and the presence of major market players. The market presence is also strengthened by the support and approvals provided by regulatory bodies. Such factors are predicted to develop the market throughout the projected timeframe.

Will the Germany Be a Lucrative Market for Autologous Conditioned Plasma?

“Increasing Research and Development Coupled with Growing Popularity of PRP therapies will Encourage the Market”

The Germany market held around 22.1% market share of the Europe market in 2022.

PRP-based therapies are becoming more significant in Germany than cell-based therapies. Growing healthcare research and development is encouraging the use of PRP in a wide range of public-interest treatments and raising awareness of its benefits.

  • Numerous professional athletes and sports personalities have expressed interest in Regenokine, a PRP-based treatment for osteoarthritis developed by a German researcher named Dr. Peter Wehling, for the treatment of fractures, ligament tears, and joint discomfort. Such novel inventions and development in the field of platelet-rich plasma therapies will further boost the market.

In the coming years, there will likely be a rise in demand for platelet-rich plasma due to the influx of patients seeking the best medical care in Germany, which will further develop the market.

How is China Emerging as a Prominent Market?

“Growing Prevalence of Arthritis in Elderly Chinese People”

China held a market share of about 46.4% of the East Asia market in 2022.

High demand for PRP therapies will arise from an ageing population, an increase in arthritic cases, and the usage of PRP therapies for alopecia. Also driving the market will be China's expanding research and development in cosmetic procedures like fat grafting, plastic surgeries, and aesthetic skin rejuvenation.

  • An elderly Chinese population-based study that was published in the journal Environmental research and Public health in 2019 found that the prevalence of knee osteoarthritis was around 21.51%.

Thus, the increasing prevalence of osteoarthritis will fuel the demand for autologous conditioned plasma in China during the projected timeframe.

Category-wise Insights

Which Composition Type is Driving the Demand within the Global Market?

“Vast Application and Low Risk Associated with the Utilization of P-PRF Therapy”

The pure platelet-rich fibrin (P-PRF) segment held around 41.5% share of the total market in 2022.

Due to its vast application in the healing process, tissue repair, and regeneration, P-PRF segment held significant revenue share. P-PRF is a low-risk procedure that is routinely combined with bone graft materials during maxillofacial surgery to speed healing and encourage bone regeneration. High demand for P-PRF treatments that accelerate musculoskeletal tissue repair is also propelling this segment's rapid expansion.

Which Source of PRP is Largely Adopted within the Global Market?

“Growing Use of Autologous PRP in Treating Diabetic Ulcers”

The autologous platelet-rich plasma held around 86.5% share of the total market in 2022.

Autologous platelet-rich plasma's applications for the treatment of chronic, non-healing diabetic ulcers is growing. A diabetic patient's stubborn non-healing ulcers can be safely and effectively treated with autologous PRP without suffering significant blood loss. The growth-inhibiting factors and fibrin in autologous PRP are in high concentrations, which speeds up the healing of wounds, owing to such factors, the segment is expected to further flourish.

Which Indication Segment is Creating High Demands for the Global Market?

“Increasing Application in Cosmetic Procedures for Quicker Outcomes”

Cosmetic surgery segment held around 29.4% share of the total market in 2022.

PRP therapies are highly employed to regenerate skin cells and rejuvenate the skin. It is frequently used with other cosmetic procedures, such as cosmetic surgery, to enhance the outcomes, encourage quicker recovery, and encourage the growth of new cells. PRP softens up the texture of the skin overall, reduces the appearance of fine lines and wrinkles on the face, and helps fill in hollow areas on the cheeks, temples, and tear through grooves. PRP also aids in the reduction of surgical and acne scars.

Which End User Significantly Utilizes the Autologous Conditioned Plasma?

“Growing Demand for Facial Aesthetics and Increasing Cases of Osteoarthritis”

The specialty clinics segment held a share of about 37.1% in 2022, within the global market.

The segment's dominance can be attributed to the quick adoption of PRP therapies in specialty clinics as a result of the recent rise in osteoarthritis cases, the high demand for non-invasive management in treatment, the rising incidences of hair loss and alopecia, and the growing use in cosmetic procedures like plastic surgeries.

Competition Landscape

For better platelet-rich plasma-based therapy options, top players in the global platelet-rich plasma market are using strategic partnerships in addition to intense research and development. Acquiring patents for new products will also become an advantageous growth tactic, enabling players to take the lead in the market.

Some key instances of development include:

  • In July 2021, Zimmer Biomet Holdings Inc., a leader in musculoskeletal healthcare worldwide, established a strategic alliance with OSSIS, which specializes in hip replacement treatment situated in New Zealand.
  • In Feb 2020, Cellmedix Holdings LLC and its Cen trepid platelet concentrator technology was acquired by EmCyteCo. This increased the company's product line and strengthened its market position.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the autologous conditioned plasma market, which are available in the full report.

Autologous Conditioned Plasma Industry Report Scope



Forecast Period

2023 to 2033

Historical Data Available for

2015 to 2022

Market Analysis

USD Million for Value

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC Countries
  • North Africa
  • South Africa

Key Market Segments Covered

  • Composition
  • Source
  • Indication
  • End User
  • Region

Key Companies Covered

  • Zimmer Biomet Inc.
  • Terumo Corporation
  • DePuy Synthes, Inc.
  • AdiStem Ltd.
  • Arthrex, Inc.
  • Stryker Corporation
  • Cesca Therapeutics, Inc.
  • Biotechnology Institute BTI
  • Dr. PRP America LLC
  • EmCyte Corporation
  • Vivostat A/S
  • Regen Lab SA
  • Royal Biologics
  • Exactech, Inc.
  • Platelex S.R.O

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Autologous Conditioned Plasma Industry Research


  • Pure Platelet-Rich Plasma (P-PRP)
  • Pure Platelet-Rich Fibrin (P-PRF)
  • Leukocyte- and Platelet-Rich Plasma (LPRP)
  • Leukocyte- and Platelet-Rich Fibrin (L-PRF)


  • Autologous Platelet-Rich Plasma
  • Allogeneic Platelet-Rich Plasma
  • Homologues Platelet-Rich Plasma


  • Skin Ulcer
    • Venous Ulcers
    • Arterial Ulcers
    • Diabetic Foot Ulcers
  • Bone Fractures and Grafts
  • Prostheses Surgeries
  • Oral Implantology
  • Sport Injuries & Trauma
  • Cosmetic Surgery
  • Others

End User:

  • Hospitals
  • Ambulatory Surgical Centre
  • Specialty Clinics
  • Orthopedic & Trauma Centers
  • Research Institutes


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Zimmer Biomet Inc
  • Terumo Corporation
  • DePuy Synthes, Inc.
  • AdiStem Ltd.
  • Arthrex, Inc.
  • Stryker Corporation
  • Cesca Therapeutics, Inc.
  • Biotechnology Institute BTI
  • Dr. PRP America LLC
  • EmCyte Corporation
  • Vivostat A/S
  • Regen Lab SA
  • Royal Biologics
  • Exactech, Inc.
  • Platelex S.R.O

- Frequently Asked Questions -

The global market is currently valued at around US$ 475.6 Million in 2022.

Sales of the market are set to witness growth at a CAGR of 11.1% and be valued at around US$ 1.52 Billion by 2033.

Demand for the global market increased at a 12.0% CAGR from 2015 to 2022.

The U.S., Germany, Canada, China, and the U.K. account for most demand within the market, currently holding around 72.3% market share.

The U.S. accounts for around 91.9% share of the North American market in 2022.

Latin America accounts for around 4.4% share of the global market in 2022.

The China market held a share of about 46.4% in the East Asia autologous conditioned plasma market in 2022.

The Germany market held around 22.1% market share of the Europe market in 2022.

Zimmer Biomed, Terumo Corporation, DePuy Synthes, Inc., and Stryker Corporation among others are the key players in the global market.

An increasing incidences of arthritis, growing geriatric population, enhanced utilization of PRPs in cosmetic surgeries and increasing sports injuries and traumas are few of the factors propelling the global market.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate